RBFC
TEVA icon

Roman Butler Fullerton & Co’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Roman Butler Fullerton & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,386
Closed -$288K – 177
2019
Q1 		$288K Sell
18,386
-749
-4% -$13.2K 0.2% 143
2018
Q4 		$348K Buy
+19,135
New +$392K 0.3% 113

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Abrams Capital Management
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Roman Butler Fullerton & Co's TEVA Position: Q2 2019 in Review

Roman Butler Fullerton & Co sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2019, closing a stake of 18,386 shares — an estimated $288K sold.

Roman Butler Fullerton & Co first reported a position in TEVA in Q4 2018 and held it in 2 quarters. The position peaked at $348K in Q4 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Roman Butler Fullerton & Co reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2019 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 18,386 Teva Pharmaceutical Industries Limited shares in Q2 2019, an estimated $288K.
  • Roman Butler Fullerton & Co first reported a position in Teva Pharmaceutical Industries Limited in Q4 2018 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Teva Pharmaceutical Industries Limited position peaked at $348K in Q4 2018.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2019.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2019, filed 22 Jul 2019.